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Abstract   
Alkaptonuria (AKU) is an inherited disorder of tyrosine metabolism caused by lack 
of active enzyme homogentisate 1,2-dioxygenase (HGD). The primary consequence of 
HGD deficiency is increased circulating homogentisic acid (HGA), the main agent in the 
pathology of AKU disease. Here we report the first metabolomic analysis of AKU 
homozygous Hgd knockout (Hgd-/-) mice to model the wider metabolic effects 
of Hgd deletion and the implication for AKU in humans. Untargeted metabolic profiling 
was performed on urine from Hgd-/- AKU (n=15) and Hgd+/- non-AKU control (n=14) mice 
by liquid chromatography high-resolution time-of-flight mass spectrometry (Experiment 
1). The metabolites showing alteration in Hgd-/- were further investigated in AKU mice 
(n=18) and patients from the UK National AKU Centre (n=25) at baseline and after 
treatment with the HGA-lowering agent nitisinone (Experiment 2). A metabolic flux 
experiment was carried out after administration of 13C-labelled HGA to Hgd-/-(n=4) 
and Hgd+/-(n=4) mice (Experiment 3) to confirm direct association with HGA. Hgd-/- mice 
showed the expected increase in HGA, together with unexpected alterations in tyrosine, 
purine and TCA-cycle pathways. Metabolites with the greatest abundance increases in 
Hgd-/- were HGA and previously unreported sulfate and glucuronide HGA conjugates, 
these were decreased in mice and patients on nitisinone and shown to be products from 
HGA by the 13C-labelled HGA tracer. Our findings reveal that increased HGA in AKU 
undergoes further metabolism by mainly phase II biotransformations. The data advance 
our understanding of overall tyrosine metabolism, demonstrating how specific metabolic 
conditions can elucidate hitherto undiscovered pathways in biochemistry and 
metabolism. 
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Alkaptonuria (AKU) is a rare disorder of tyrosine metabolism caused by congenital lack 
of activity of the enzyme homogentisate 1,2-dioxygenase HGD (E.C.1.12.11.5).1 The 
biochemical consequence of HGD deficiency is increased homogentisic acid (HGA) in 
the circulation, the pathognomonic sign of the disease and central to its 
pathophysiological features.2 HGA has a high affinity for collagenous tissues, where its 
deposition produces striking pigmentation,3 a process called ochronosis. Cartilage of 
load-bearing joints is particularly susceptible to ochronosis. Presence of HGA-derived 
pigment in these joints alters the physicochemical properties of cartilage that support 
normal transmission of load and results in an inevitable and severe early-onset 
osteoarthropathy.4,5 
Metabolomics has emerged as an invaluable approach for studying AKU. In our 
laboratory we have developed a targeted approach with specific mass spectrometric 
assays as an aid for diagnosis and monitoring of AKU.6,7 These assays offer precise 
quantification of tyrosine pathway metabolites including HGA in serum and urine. More 
recently, a strategy has been developed for profiling and chemical identification of up to 
619 related and more general metabolites by high-resolution accurate mass and 
retention time using liquid chromatography quadrupole time-of-flight mass spectrometry 
 
Abbreviations: AKU, alkaptonuria; HGD, homogentisate 1,2-dioxygenase; HGA, 
homogentisic acid; LC-QTOF-MS, liquid chromatography quadrupole time-of-flight mass 
spectrometry; MS/MS, tandem mass spectrometry; AMRT, accurate mass / retention 
time; PCA, principal component analysis; RT, retention time; FDR, false-discovery rate; 
FC, fold change; QC, quality control; CV, coefficient of variation; MSC, Molecular 
Structure Correlator; HPPD, hydroxyphenylpyruvic acid dioxygenase 
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(LC-QTOF-MS).8 Application of this technique to AKU serum9 and urine8 enabled the 
discovery of previously unknown metabolite and metabolic pathway alterations following 
treatment with the HGA-lowering agent nitisinone. Metabolic profiling therefore has 
potential in AKU as both a phenotyping and biomarker discovery tool. However, to our 
knowledge, untreated AKU has not been compared with non-AKU at the metabolome 
level before. 
The investigations into such possible changes in the metabolome as a result of AKU will 
be greatly facilitated by use of an animal model of AKU developed in our laboratory by 
homozygous knockout of the Hgd gene (Hgd-/-) in mice. The genetically altered Hgd-/- 
mouse recapitulates human AKU, with elevated plasma and urine HGA, development of 
ochronosis and its inhibition by nitisinone.10,11 It was important to establish the metabolic 
profile of this model, so we first compared the urinary profiles of AKU homozygous Hgd 
knockout mice (Hgd-/-) with non-AKU heterozygous knockout (Hgd+/-) control mice 
(Experiment 1). Secondly, we looked to confirm any AKU-related metabolite differences 
by assessing whether the direction of alteration was reversed while on the HGA-
lowering drug nitisinone treatment in Hgd-/- mice or patients (Experiment 2). Thirdly, a 
metabolic flux experiment was carried out (Experiment 3), in which mice were injected 
with stable isotope 13C-labelled HGA to ascertain whether metabolites increased in Hgd-
/- were directly derived from HGA.  
The overall aim of these experiments (Figure 1) was to investigate in a controlled study 
the metabolic markers of disease in AKU and if metabolite alterations could elucidate 
possible novel disease mechanisms and thereby improve current strategies for 
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monitoring the disease process and subsequent treatment response in patients with 
AKU. 
2. Material and methods 
2.1 Animal housing and husbandry 
All mice were housed in the University of Liverpool’s Biomedical Services Unit under 
pathogen-free conditions, in cages of up to five mice, with 12-hr light/dark cycle, and 
food and water available ad libitum. Mice were drug/test-naïve at baseline in each 
experiment. 
2.2 Materials 
Deionised water was purified in-house by DIRECT-Q 3UV water purification system 
(Millipore, Watford, UK). Methanol, acetonitrile, isopropanol (Sigma-Aldrich, Poole, UK), 
formic acid (Biosolve, Valkenswaard, Netherlands) and ammonium formate (Fisher 
Scientific, Schwerte, Germany) were LC/MS grade. 13C6 labelled HGA for metabolic flux 
analysis was purchased from Toronto Research Chemicals (Toronto, Canada). 
2.3 Urine collection and sample preparation for metabolomics (Experiment 1) 
For metabolomic analysis of the targeted Hgd knockout phenotype,10 urine was 
collected from 15 Hgd-/- (mean age ±SD 12.8±0.1 weeks) and 14 Hgd+/- (mean age 
11.6±0.3) weeks) male C57BL/6 mice. Drinking water was supplied ad libitum and the 
mouse urine was collected on a single-collection basis onto plastic wrap, pipetted into 
sample tubes and stored at -80°C. Increased urinary HGA was expected to be the most 
marked metabolic alteration in Hgd-/-, but we were also interested to study the wider, 
potentially more subtle metabolic alteration both within the tyrosine pathway and in non-
7 
directly associated pathways. The number of mice studied was therefore considered 
appropriate to sufficiently power this experiment, given that mouse urine collection is a 
non-invasive procedure. 
Pooled samples were created in each profiling experiment for quality control (QC) 
purposes. For Hgd-/- and Hgd+/- groups a separate representative pool was created by 
pooling 20µL of each individual urine sample. An overall pool was also created for each 
experiment by pooling equal proportions of the above group pools. Analysis of individual 
and pooled samples was performed following dilution of 1:9 urine:deionised water as 
previously described.8 
2.4 Investigating the effect of nitisinone on metabolites showing alteration in 
Hgd-/- mice and patients with AKU (Experiment 2) 
The effect of nitisinone treatment on urinary metabolites altered in Hgd-/- mice (Figure 1, 
Experiment 1) was studied in the data from a previous profiling experiment described by 
Norman et al.8 These data were from urine from 18 BALB/c Hgd-/- mice (mean age 
27±12 weeks, 9 female, 9 male) with Hgd disruption by ENU mutagenesis11 and from 25 
patients attending the UK National Alkaptonuria Centre (NAC; mean age 51±15 years, 
13 female, 12 male). The disease phenotypes of Hgd-/- mice from targeted knockout and 
ENU mutagenesis models are identical.10 Data were from urine collected at baseline, 
then on nitisinone at one week in mice (supplied ad libitum in drinking water at 4mg/L) 
and at 24 months in patients (2mg daily dose). These datasets were acquired under 
identical LC-QTOF-MS analytical conditions to those employed in the present study. 
2.5 Design of in vivo metabolic flux experiment and sample collection 
(Experiment 3) 
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Eight C57BL/6 mice were studied in the HGA metabolic flux experiment; four Hgd-/- 
(mean age 56±2.3 weeks, 1 female, 3 male) and four Hgd+/- (mean age 58±0 weeks, 4 
female). A 1.96mg/mL 13C6 HGA tracer solution was prepared in sterile saline and 
injected into the tail vein. Injection volume was adjusted for each mouse to achieve a 
final blood concentration of 1mmol/L, assuming a total blood volume of 75mL/kg.12 
Venous tail bleed samples were then taken at 2, 5, 10, 20, 40 and 60 min post-injection, 
keeping sampling volumes within LASA guidelines.12 Mice were kept anaesthetised with 
isoflurane throughout the experiment. Blood was collected into Microvette 300µL lithium 
heparin capillary tubes (Sarstedt, Nümbrecht, Germany) and centrifuged at 1500x g for 
10 min. Plasma supernatant was removed and stored at -80°C prior to analysis. 
Individual plasma samples were analysed following 1:9 plasma:deionised water. 
2.6 LC-QTOF-MS analyses 
Analysis of plasma and urine was performed on an Agilent 1290 Infinity HPLC coupled 
to an Agilent 6550 QTOF-MS equipped with a dual AJS electrospray ionization source 
(Agilent, Cheadle, UK). Reversed-phase LC was performed on an Atlantis dC18 column 
(3x100mm, 3µm, Waters, Manchester, UK) maintained at 60°C. Mobile phase 
composition was (A) water and (B) methanol, both with 5mmol/L ammonium formate 
and 0.1% formic acid. The elution gradient began at 5% B 0-1 min and increased 
linearly to 100% B by 12 min, held at 100% B until 14 min, then at 5% B for a further 5 
min. MS data acquisition was performed in positive and negative ionisation polarity with 
mass range 50-1700 in 2 GHz mode with acquisition rate at 3 spectra/second. Sample 
injection volume was 2µL, and the autosampler compartment was maintained at 4°C. 
Additional data acquisition parameters are detailed in Appendix 1. 
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Data-dependent tandem mass spectrometry (MS/MS) was performed on pooled urine 
samples, with compound hits from Experiment 1 as [M+H]+ and [M-H]- accurate mass 
precursor ion targets; no more than six compound targets per injection. Fixed collision 
energies of 10, 20 and 40 V were applied. Acquisition rates were 6 spectra/second in 
MS and 4 spectra/second in MS/MS.  
2.7 Design of LC-QTOF-MS profiling analyses 
Samples from Experiments 1 (Hgd-/- versus Hgd+/-) and 3 (13C6 HGA metabolic flux 
analysis) were analysed in separate batches, each comprising negative then positive 
polarity. The analytical sequence of each profiling batch was designed according to 
published guidance13 and following the procedure described previously by Norman et 
al.8 
2.8 Data processing and statistical analyses 
Mining of metabolite features in raw data was performed using two parallel approaches 
(Figure 1, Experiment 1). A targeted approach was used to extract signals matching a 
466-compound AMRT database previously generated in our laboratory from IROA 
Technology MS metabolite library of standards, accessible via 
https://doi.org/10.6084/m9.figshare.c.4378235.v2,8 or a compound database comprising 
accurate masses of additional compounds with potential relevance to AKU. A 
complementary non-targeted approach was used to extract unknown metabolites. 
2.8.1 Targeted feature extraction 
Targeted feature extraction was performed in Profinder (build 08.00, Agilent) using the 
chemical formulae of compounds from the AMRT database described above. Extraction 
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parameters were accurate mass match window ±10ppm and retention time (RT) window 
±0.3 min. Allowed ion species were: H+, Na+, and NH4+ in positive polarity, and H- and 
CHO2- in negative polarity. Charge state range was 1-2, and dimers were allowed. ‘Find 
by formula’ filters were: score >60 in at least 60% of samples in at least one sample 
group (samples were grouped by Hgd-/- or Hgd+/- and pre- or on nitisinone). 
Seventy-five additional metabolites of potential interest in AKU or from wider tyrosine 
metabolism were appended to the database for targeted extraction. Forty-three were 
from the following pathway databases available from Pathways to PCDL (build 07.00, 
Agilent): ‘citrate degradation’, ‘noradrenaline and adrenaline degradation’ and the 
‘superpathway of phenylalanine, tyrosine and tryptophan biosynthesis’ (Appendix 2). Six 
metabolites were added as they were predicted to show potential alteration in Hgd-/- due 
to association with tyrosine conjugation (acetyl-L-tyrosine, and γ-glutamyl-tyrosine) 
based on a previous publication8 or association with ochronotic pigment derived from 
HGA (2,5-dihydroxybenzaldehyde, benzoquinoneacetic acid, hipposudoric acid and 
norhipposudoric acid). Twenty-six metabolites were from a list of potential 
biotransformation products directly derived from HGA and compiled using the 
Biotransformation Mass Defects application (Agilent; Appendix 3). This tool provides a 
list of potential metabolic biotransformation products covering both phase I and II 
metabolism for a given compound based on empirical formula. The data were mined for 
these additional metabolites with putative identification by accurate mass (±5ppm) only. 
2.8.2 Non-targeted feature extraction 
Non-targeted extraction was performed by recursive feature extraction in Profinder 
(build 08.00). Extraction parameters are detailed in Appendix 4. 
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2.8.3 Isotopologue feature extraction on data from 13C6 HGA metabolic flux analysis 
Data from Experiment 3 (Figure 1) were mined using batch isotopologue extraction in 
Profinder (build 08.00). Here, compounds that showed significant differences between 
Hgd-/- and Hgd+/- mice (Experiment 1) were investigated for potential association with 
the 13C6 HGA tracer by examining the relative abundances of their M+0 to M+6 
isotopologues. Extraction was performed with accurate mass and RT match windows of 
±5ppm and ±0.3 min respectively against an AMRT database consisting only of these 
compound targets. 
2.8.4 Data QC and statistical analyses 
First, initial QC was performed on all datasets in Profinder by manual curation of the 
dataset to remove visually low quality peaks and to correct integration issues across the 
dataset where appropriate. 
Urine profiling datasets were then exported from Profinder as .csv files and imported 
into Mass Profiler Professional (build 14.5, Agilent) for additional QC and subsequent 
statistical analyses. First, creatinine peak area from this analysis was used as an 
external scalar for each mouse sample to account for differences in urine concentration, 
as described previously.8 Additional QC was performed using data from pooled 
samples, which were interspersed throughout each analytical sequence. Compounds 
were retained if a) observed in 100% of replicate injections for at least one sample 
group pool, and b) peak area coefficient of variation (CV) remained <25% across 
replicate injections for each sample group pool. Statistically significant compounds were 
then identified in each dataset by t-tests; two sample t-tests for Hgd-/- versus Hgd+/- 
comparisons, and paired t-tests for pre- versus on nitisinone comparisons. Multiple 
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testing correction was performed using Benjamini-Hochberg false discovery rate (FDR) 
adjustment. FC’s were log2-transformed and based on peak area. FC cut-off was not 
applied for compounds with FDR-adjusted p<0.05, in order to retain compounds that 
showed consistent although relatively low magnitude abundance differences between 
comparison groups. Principal Components Analysis (PCA) was performed on each 
filtered dataset using four-component models. 
2.8.5 In vivo metabolic flux data analysis  
The results from isotopologue extraction on plasma 13C6 HGA metabolic flux data were 
reviewed visually in Profinder for clear evidence of an isotope label likely to be derived 
from HGA. This data review was performed for compound matches individually using 
the predicted number of 13C atoms derived from the HGA tracer based on chemical 
structure. 
2.8.6  MS/MS data analysis  
Raw MS/MS data files were processed by MassHunter Qualitative Analysis Workflows 
(Build 08.00), using the targeted MS/MS compound discovery algorithm. For 
compounds from the in-house AMRT database, MS/MS spectral library matching was 
performed against the METLIN metabolite PCDL accurate mass library (build 07.00), 
which contains over 30,000 compound entries, of which 1804 contain experimental 
MS/MS spectral data. For the HGA-derived compounds, for which no known chemical 
standards or compound library entries currently exist, structure identifications were 
performed using Agilent Molecular Structure Correlator (version B.07.00, build 31). This 
approach involves matching between accurate mass MS/MS fragment ions obtained 
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from collision-induced dissociation MS with one or more proposed molecular structures 
based on a systematic bond disconnection approach.14 
2.9 Study approval 
All animal work was carried out in accordance with UK Home Office Guidelines under 
the Animals (Scientific Procedures) Act, 1986 and with institutional approval. 
Metabolomic analyses on patient samples was approved by the Royal Liverpool and 
Broadgreen University Hospital Trust’s Audit Committee (audit no. ACO3836) and was 
part of the diagnostic service to patients attending the UK National Alkaptonuria Centre 
in Liverpool. 
3. Results 
PCA showed clear separation in principal component 1 between the urine profiles of 
Hgd-/- and Hgd+/- mice from targeted (Figures 2A & 2B) and non-targeted feature 
extraction. Results from targeted and non-targeted extraction are presented separately 
in the following sections (number of compounds obtained in each extraction method 
summarised in Appendix 5). Data from all animals in each experiment were included in 
the analysis. 
3.1 Targeted feature extraction 
Targeted feature extraction was performed to search for metabolites based on AMRT 
(accurate mass ±10ppm, RT ±0.3 min) or accurate mass (±5ppm) alone. 27/250 and 
15/243 metabolites showed abundance differences (FDR-adjusted p<0.05) between 
Hgd-/- and Hgd+/- in negative and positive polarity, respectively. Table 1 shows the 
altered metabolites ranked by FC. PCA loadings plots (Figures 2C & 2D) and volcano 
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plots (Figures 2E & 2F) show that the greatest differences between Hgd-/- and Hgd+/- 
urine were in metabolites associated with HGA in negative and positive polarity. HGA 
and six predicted HGA biotransformation products were markedly elevated in Hgd-/-. 
Interestingly, HGA-sulfate (FC=9.3, p<0.0001) showed a greater FC increase than HGA 
(FC=7.9, p<0.0001). Other HGA products increased with FC >1.5 and p<0.0001 were 
HGA-glucuronide, HGA-hydroxyl-sulfate, HGA-N-acetylcysteine and HGA-hydrate. 
Acetyl-HGA was elevated in Hgd-/- (FC=2.3, p<0.0001), but did not pass QC filtering by 
CV <25% across replicate injections of pooled QC samples; a decrease in signal across 
the run indicated a stability issue (despite the auto-sampler being maintained at 4°C). 
Excluding HGA, 26 significantly altered compounds were AMRT-matched with 
metabolites from the 466-compound library developed in-house. The most significantly 
altered (p<0.05 and log2 FC>1.5) of these were:  thymidine-5’-diphospho-alpha-D-
glucose, DL-3,4-dihydroxymandelic acid, 2-aminophenol, p-hydroxyphenylacetic acid 
(increased in Hgd-/-), malic acid, citric acid and inosine 5’-monophosphate (decreased in 
Hgd-/-). 
MS/MS fragmentation data were acquired to confirm the compound identifications of the 
significantly altered metabolites. For the HGA-derived metabolites, the proposed 
structures (Figure 4) were imported into the in-house AMRT compound library as .mol 
files for matching of experimental MS/MS spectra against in silico fragmentation 
predictions using Molecular Structure Correlator (MSC). MSC match scores >85% were 
obtained for HGA-glucuronide (91.2%), HGA-sulfate (86.7%) and HGA-hydroxylsulfate 
(85.9%), strongly supporting the chemical structures proposed for these compounds. 
Intermediate scores were obtained for the proposed structure for acetyl-HGA (54.3%) 
15 
and hydroxymethyl-HGA (53.9%). Lower MSC scores were obtained for the structures 
proposed for HGA-N-acetylcysteine (32.4%) and HGA-hydrate (20.3%). The MSC score 
obtained for each of these HGA-derived structures was either the only compound 
structure match or was greater than the highest scoring match from the MassHunter 
METLIN metabolite library. For the significantly altered metabolites that were not HGA 
biotransformation products, 15 of the AMRT-matched compounds were confirmed by 
MS/MS spectral library match, with a match threshold of ≥65% (Table 1 & Appendix 6).  
3.2 Non-targeted feature extraction 
Non-targeted feature extraction yielded 359 and 213 compounds post-QC in negative 
and positive polarity respectively; mass range = 54-3108 Da and RT range = 1.1-11.5 
min. Comparison of Hgd-/- and Hgd+/- revealed compounds with clear abundance 
differences (p<0.05, log2 FC>1.5); 9 in negative polarity (6 increased in Hgd-/-, 3 
decreased in Hgd-/-) and 2 in positive polarity (both increased in Hgd-/-). The mass range 
of these significant compounds was 242-507 Da, and RT range was 1.7-9.6 min (Table 
1). Searching of the MassHunter METLIN metabolite PCDL accurate mass library (build 
07.00) yielded no matches for these compounds based on library MS/MS spectral 
matching or accurate mass (<5ppm) alone.  
3.3 The effect of nitisinone treatment on metabolites altered in Hgd-/- mice 
To investigate the effect of nitisinone treatment on the metabolites shown to be altered 
here in Hgd-/-, they were searched in the data from previous mouse and human urine 
profiling experiments (Experiment 2; Figure 1).8  
Eight compounds from targeted feature extraction that were altered in Hgd-/- versus 
Hgd+/- mice were significantly altered in the opposite direction in urine from both Hgd-/- 
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mice and patients with AKU on nitisinone (based on peak area pre- versus on 
nitisinone, Benjamini-Hochberg FDR-adjusted p<0.05; Table 2); seven decreased, and 
one increased. The seven decreased metabolites were HGA, the HGA 
biotransformation products HGA-sulfate, HGA-glucuronide, HGA-hydrate and 
hydroxymethyl-HGA, and also xanthosine and 3,5-cyclic-AMP. The increased 
metabolite was 3-methyl-glutaric acid. Interestingly, p-hydroxyphenylacetic acid and 4-
hydroxybenzaldehyde were increased both in Hgd-/- versus Hgd+/- and also on nitisinone 
in Hgd-/- mice and patients. 
Nineteen compounds that were altered in Hgd-/- versus Hgd+/- mice were significantly 
altered in the opposite direction on nitisinone in urine from either Hgd-/- mice (n=14; 9 
decreased, 5 increased on nitisinone) or patients (n=5; 4 decreased, 1 increased on 
nitisinone) only (Table 2). These compounds comprised the remaining HGA 
biotransformation products, which were all decreased on nitisinone. On nitisinone, 
acetyl-HGA was decreased in patients only, and HGA-hydroxyl-sulfate and HGA-N-
acetylcysteine were decreased in mice only. 
3.4 Confirmation of HGA biotransformation products by 13C6 HGA metabolic 
flux analysis (Experiment 3) 
Data from isotopologue extraction were compared between plasma collected from the 
same mice across the time intervals available (2-60 min). The M+6 isotopologue was of 
particular interest as mice were injected with 13C6-labelled HGA. A clear M+6 peak for 
HGA was observed over the sampling time course in plasma from Hgd-/- and Hgd+/- 
mice, although the signal decreased from 10-20 min post-injection (Figure 3). As 
indicated in Figure 2 (compounds in bold text), two HGA biotransformation products that 
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were increased in Hgd-/- urine were observed with clear M+6 peaks over the time 
course; HGA-glucuronide and HGA-sulfate. These data confirm that the compounds are 
derived from HGA. HGA-sulfate showed a similar time course profile to HGA; the native 
M+0 isotopologues were absent from Hgd+/- plasma at all time points, in contrast to the 
M+6 isotopologue whose profile appeared to closely follow that of the HGA M+6 peak 
over the time course in both Hgd-/- and Hgd+/- (Figure 3). For HGA-glucuronide, the 
native M+0 isotopologue was also absent from Hgd+/- plasma, but the M+6 isotopologue 
was only observed in Hgd-/- (Figure 3), indicating that glucuronidation of the HGA tracer 
was evident only for Hgd-/- mice. 
4. Discussion 
The data reported form part of the first recorded metabolome-wide comparison obtained 
from untreated AKU versus non-AKU animal models and shows, for the first time, that 
the overproduced HGA in AKU undergoes predominantly phase II metabolic 
biotransformations. Phase II metabolism involves conjugation reactions to form sulfate, 
glucuronide, glutathione, mercapturic acid, amino acid, methyl and acetyl 
conjugates.15,16 The predominant sulfation and glucuronidation biotransformations 
observed for HGA are also essential aspects of metabolism of other phenolic acids, bile 
acids, steroids and numerous other endogenous biochemicals. The phase I metabolism 
reactions of hydroxylation, oxidation, reduction and hydrolysis were relatively minor. 
Further, our data indicate that the biochemical consequences of HGD deficiency extend 
beyond tyrosine metabolism.  
4.1 HGA biotransformation products from phases I and II metabolism 
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The clearest differences between the urine metabolomes of Hgd-/- versus Hgd+/- mice 
were in HGA and seven previously unreported HGA-derived biotransformation products, 
increased in Hgd-/-.  The decreased output in HGA-sulfate, HGA-glucuronide, HGA-
hydrate, acetyl-HGA and hydroxymethyl-HGA for patients on treatment with nitisinone 
(Experiment 2) indicates that these HGA phase II biotransformations occur in human 
AKU. The detection of 13C6-labelled forms of HGA-glucuronide and HGA-sulfate in 
plasma following 13C6-HGA injection in mice (Experiment 3) confirm products derived 
from HGA. The 13C6-HGA-sulfate was observed both in Hgd-/- and Hgd+/- mice, following 
the profile of the 13C6-HGA across the sampling time course. The 13C6-HGA-glucuronide 
was observed only in Hgd-/-, suggesting prior upregulation of glucuronyltransferase 
activity was required to enhance HGA clearance in AKU.  
The putative structures of these newly idientified biotransformation compounds, 
together with the enzyme classes for their formation are shown in Figure 4, although the 
exact enzymes are not yet described. The proposed biotransformation compound 
structures are the closest known matches, based on correlation between the observed 
experimental MS/MS spectra and the accurate mass fragment ions predicted in silico 
from the 30,000+ metabolite structures in the Metlin and in-house compound libraries. In 
the absence of reference standards for these compounds, the MS/MS data confirm the 
structures proposed for HGA-glucuronide, HGA-sulfate and HGA hydroxylsulfate, with 
MSC scores >85%. To our knowledge, these are the first data on HGA metabolism not 
involving conversion to maleylacetoacetic acid in the traditional tyrosine degradation 
pathway (Figure 5). 
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The markedly increased output of the HGA-glucuronide (FC=5) and HGA-sulfate 
(FC=9.3), as well as HGA (FC=7.9), in AKU Hgd-/- mice has implications for the 
regulation of plasma HGA and products. Despite efficient renal excretion of HGA-related 
compounds in AKU,17 the circulating HGA remains elevated; mean serum HGA 
concentration is 30µmol/L in untreated AKU18 and <1.5µmol/L in healthy subjects.19,20 
The increased plasma HGA persists as the primary toxic agent in AKU; its oxidation 
produces ochronotic pigment, which becomes bound within the extracellular matrix of 
collagenous tissues. This process of damage is thought to occur via HGA oxidation to 
highly reactive benzoquinone and free radical intermediates.5 These species are 
capable of inducing oxidative changes to proteins and lipids,21,22 are known to self-
perpetuate osteoarthropathy associated with ochronosis5 and account for cases of 
acute fatal metabolic consequences reported in the literature.23 The data reported here 
show that metabolism of HGA by phase II biotransformations, particularly 
glucuronidation and sulfation reactions, is a major route in an attempt to render the 
increased HGA chemically inert (detoxify), in effect to protect from consequences of 
increased benzoquinone production. The HGA-derived products observed must be 
included in metabolic profiling in AKU patients to understand the total production of 
HGA and how this impacts on predicting the amount of HGA-derived pigment produced 
in vivo.  
It is not clear whether the HGA biotransformations described are simply unmasked in 
AKU due to the markedly increased HGA, or whether they are actively and exclusively 
recruited in AKU for HGA detoxification. Nevertheless, identification of the specific 
enzymes that catalyse the biotransformations could inform future AKU therapeutic 
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interventions aimed at enhancing HGA metabolism. Glucuronidation, for example, is 
quantitatively one of the most important phase II biotransformation reactions, performed 
by 15 UPD-glucuronosyltransferase enzymes for conjugation of a large number of 
exogenous and endogenous compounds in humans.24,25 A number of agents, including 
naturally occurring dietary compounds, are known to be potent inducers of UPD-
glucuronosyltransferases and other phase II enzymes.26–28 There are encouraging 
examples of targeting specific enzymes of phase II metabolism in other conditions of 
endogenous compound accumulation, including UDP-glucuronosyltransferase 1A1 in 
neonatal hyperbilirubinaemia29 and sulfotransferases in oestrogen-dependent breast 
cancer.30  
The liver is the primary site of phase I and II metabolism, both by tissue mass and 
activity.31 Extrahepatic metabolism in tissues such as the kidney and intestinal 
epithelium is also significant.32 It is possible that site-specific enzyme activity explains 
the interesting finding that conjugation products from the 13C6-labelled HGA were 
observed mainly for glucuronidation and sulfation. The other biotransformation products 
observed in urine were not detected in the plasma tracer experiment, despite their clear 
concomitant urinary reduction on nitisinone confirming direct association with HGA. In 
the metabolic flux experiment, HGA was administered intravenously, which is likely to 
favour formation of products from hepatic metabolism. It would be interesting therefore 
to give HGA by various routes of delivery and trace its metabolism in various tissues 
and biofluids to assess the metabolic activity contributed by different anatomical 
compartments. It is also worth noting that the glycine conjugate of HGA, a potential 
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HGA biotransformation product, was not detected in Hgd-/-; glycine conjugation is a 
known detoxification mechanism of a number of other aromatic acids.33,34  
The observation of marked elevations in five of the seven HGA-derived compounds 
which were initially discovered in mice, including the major biotransformation products 
from HGA sulfation and glucuronidation, in untreated patients with AKU (Experiment 2) 
supports use of the Hgd-/- mouse as an accurate model of human AKU biochemistry. 
Our preclinical studies of the Hgd-/- mouse have helped us to understand the metabolic 
and wider pathophysiological features of AKU in humans, the natural course of the 
disease and its response to treatment. The mice studied in Experiment 1 were male 
only in order to enable a highly controlled and powered examination of the metabolic 
impact of Hgd knockout. The inclusion of the previously published data from equal male 
and female Hgd-/- mice in Experiment 2 confirms that the metabolic alterations observed 
for AKU mice in Experiment 1 are not restricted to males. Further, in Experiment 3 we 
observed both native non-labelled and 13C-labelled HGA-glucuronide and HGA-sulfate 
products for male and female Hgd-/- mice. As noted in our published discussion of the 
dataset featured in Experiment 2, the metabolomic difference between urine from male 
and female mice is largely attributable to the markedly increased urinary histamine in 
female mice, and no difference in metabolism of tyrosine or HGA.8  
4.2 Associated alteration to tyrosine, purine and TCA cycle metabolism in AKU 
This study showed for the first time that in untreated AKU there is alteration to tyrosine, 
purine and TCA cycle metabolites (Figure 5). Previous metabolomic studies in AKU 
have focused solely on the impact of nitisinone on the metabolome.8,9,35–37 Nitisinone 
reversibly inhibits hydroxyphenylpyruvic acid dioxygenase (HPPD; E.C. 1.13.11.27), the 
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enzyme that produces HGA, and it is currently the most effective treatment for AKU. 
Nitisinone reduces plasma and urine HGA concentrations,18,19,38–40 completely arrests 
ochronosis in AKU mice11,41 and more recently was shown to decrease ochronosis and 
improve clinical signs of AKU in patients enrolled in SONIA 2, the 4-year phase 3 
international randomised controlled trial of nitisinone in AKU (ClinicalTrials.gov identifier: 
NCT01916382).42 We showed previously in serum and urine that nitisinone induced an 
extended network of metabolic alteration within tyrosine and neighbouring pathways, 
including tryptophan, purine and TCA cycle.8,9 This alteration is a concern in AKU, and 
particularly in hereditary tyrosinaemia type-1, another inherited disorder of tyrosine 
metabolism, in which nitisinone treatment is essential from early infancy.43 
The increases in tyrosine metabolites reported here, excluding HGA, were unexpected 
in untreated AKU. Increases in metabolites upstream of HPPD previously reported in 
nitisinone-treated AKU were thought to be a direct consequence of the inhibition of 
HPPD by nitisinone and the consequential hypertyrosinaemia.8,9 For the first time, the 
present data show that targeted Hgd disruption in Hgd-/- mice induces metabolic 
changes upstream of HGA, despite no increase in tyrosine, hydroxyphenylpyruvic acid 
or hydroxyphenyllactic acid. The cause of these unexpected changes to tyrosine and 
peripheral neurotransmitter metabolism in untreated AKU is not clear. At the 
supraphysiological concentrations observed in AKU, HGA could potentially act on other 
enzymes of neurotransmitter metabolites and alter their activity. Alternatively, the 
changes could relate to an unknown feature of the disease.  
In nitisinone-treated AKU, the purine metabolite changes previously reported were 
mainly decreased concentrations.8 The present data indicate a more complex pattern of 
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purine alteration in untreated AKU; increased 3,5-cyclic AMP and xanthosine, and 
decreased 2,3-cyclic AMP and inosine 5’-monophosphate. Purine catabolism is 
important in the homeostatic response to various states of mitochondrial oxidative 
stress, with shifts occurring to favour breakdown to xanthine and uric acid, the final 
breakdown products of purines.44,45 The increased xanthosine and decreases in the 
upstream purine pathway metabolites 2,3-cyclic AMP and inosine 5’-monophosphate 
reported here for Hgd-/- mice is consistent with a shift in purine catabolism as a 
protection mechanism against HGA-induced oxidative stress in untreated AKU, as 
xanthine derivatives have anti-oxidant properties.46 There is growing evidence that 
HGA-induced oxidative stress is an important feature of AKU (see ref. 22 for an 
extensive review on this subject), and that it exacerbates ochronosis, the central AKU 
disease process.47 The increased xanthosine observed here is likely a new metabolic 
marker of HGA-induced oxidative stress in AKU; urinary xanthosine is markedly 
increased in other oxidative diseases, including gout,48 chronic kidney disease and 
diabetes nephropathy,49 and it is markedly decreased following administration of 
nephroprotective therapy.  
Decreases in TCA-related metabolites in Hgd-/- is the first indication of perturbed energy 
metabolism in untreated AKU. Decreases in citramalic acid, citric acid and N-acetyl-L-
glutamic acid were reversed on nitisinone in Hgd-/-, suggesting for the first time that 
nitisinone is at least partially restorative. Blood and urine concentrations of TCA 
metabolites are generally considered to directly reflect overall TCA cycle activity.50 
Inhibited TCA cycle activity could be due to overall mitochondrial biogenesis, decreased 
expression of genes encoding TCA cycle enzymes, dysregulation of enzyme activity or 
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reduced substrate availability. The latter explanation seems the most likely in AKU, in 
which HGD deficiency prevents further metabolism of HGA to the TCA cycle 
intermediate fumaric acid. Decreased bioavailability of fumaric acid may then explain 
the decreases observed for other TCA cycle metabolites. Previous analyses have 
investigated potential changes to TCA cycle metabolites in AKU, but these were limited 
to studying the effect of nitisinone; serum concentrations of TCA metabolites succinic 
acid and α-ketoglutaric acid were decreased in patients with AKU on nitisinone.9 The 
significance of these decreases is not known, and further studies should investigate 
whether the alteration to urinary TCA cycle metabolites reported here also applies to 
serum in untreated AKU. 
Decreased urinary citrate is a well-known risk factor for kidney stone formation. It is 
possible that the decreased citric acid reported here for Hgd-/- mice is associated with 
the increased risk of kidney stones in AKU.51 Hypocitraturia is generally defined as citric 
acid excretion <320mg (1.67mmol) per day in adults.52 The present profiling data are 
semi-quantitative; targeted quantitative assays are required to determine exact urinary 
citric acid concentrations in AKU patients and the additional therapeutic value of 
nitisinone in this regard. 
5. Conclusions 
In conclusion, we have shown that targeted homozygous disruption to the Hgd gene 
induces previously unknown metabolite changes in a complex network of pathways 
associated with altered tyrosine metabolism. These changes include the 
biotransformation of HGA by mainly phase II metabolic processes and relatively little by 
phase I. This observation will encourage further as yet unexplored potential treatment 
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targets for detoxification of HGA, the culprit molecule in AKU. The wider take-home 
message of this study is that inherited metabolic diseases, such as AKU, present 
unique windows into metabolism that can uncover associations between metabolic 
pathways in physiology and biochemistry more generally.  
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Figure 1. Schematic overview of the overall study design, incorporating 
Experiments 1-3. In Experiment 1, urine was collected from Hgd-/- and Hgd+/- mice and 
profiled by LC-QTOF-MS. Targeted and non-targeted feature extraction was performed 
on the data in parallel and subsequent unpaired t-tests were employed to identify 
differentially abundant compounds between Hgd-/- and Hgd+/-. These compounds were 
then further investigated in LC-QTOF-MS data from two additional datasets; a 
previously published study examining the effect of nitisinone on the urine metabolome 
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of Hgd-/- BALB/c mice and patients with AKU8 (Experiment 2) and a plasma flux analysis 
using a 13C6 labelled HGA tracer (Experiment 3). 
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Figure 2. Clear differences between the urine metabolomes of Hgd-/- and Hgd+/- 
mice. A-D: PCA on data from targeted feature extraction, with PCA plots showing 
separation between Hgd-/- and Hgd+/- mice by component 1 in A, negative, and B, 
positive ionisation polarities. Lower plots show the corresponding PCA loadings of 
metabolites on components 1 and 2 in C, negative, and D, positive polarity. E-F: 
volcano plots illustrating selection of statistically significant urinary metabolites between 
Hgd-/- and Hgd+/- mice based on p-value and fold change. E, negative polarity; F, 
positive polarity. Compounds with p<0.05 (Benjamini-Hochberg FDR adjusted) and log2 
fold change >1.5 are labelled, with red and blue indicating increased and decreased 
abundance, respectively, in Hgd-/-. Turquoise indicates adjusted p<0.05 but log2 fold 
change <1.5. 
Bold text indicates that the increase observed in Hgd-/- was confirmed in mouse plasma 
following injection with 13C6 HGA tracer. 






Figure 3. Isotopologue extraction results on plasma from the in vivo metabolic 
flux experiment using injected 13C6-labelled homogentisic acid (HGA). Data shown 
are from Hgd-/- and Hgd+/- samples taken at intervals of 2, 5, 10, 20, 40 and 60 (when 
possible) min after injection. Extracted ion chromatograms (EIC’s) represent the M+0 
(native compound) and M+6 (13C6-labelled form) isotopologue signals for HGA, HGA-
sulfate and HGA-glucuronide. EIC’s show clear M+6 peaks for these compounds 
following injection (but only from Hgd-/- mice for HGA-glucuronide), confirming that they 





Figure 4. Predicted structures of newly-identified HGA biotransformation 
products resulting from phase I and II metabolism. Predicted structures were the 
closest matches against the acquired experimental MS/MS data, based on scores 
obtained using Agilent Molecular Structure Correlator (MSC). The proposed sites for 
metabolism/conjugation were based on match scores obtained for a list of possible 






Figure 5. Summary of metabolites altered in Hgd-/- mouse urine grouped by their 
associated pathways. Left: the tyrosine degradation pathway showing lack of the 
enzyme HGD in AKU and the consequential increase in HGA. Right (boxes): observed 
metabolite alterations grouped by pathway; red and blue indicate increased and 
decreased abundance respectively. Tyrosine metabolites, including HGA and HGA 
biotransformation products, were elevated. Metabolites associated with the TCA cycle 
were decreased. A combination of increased and decreased abundance was observed 





Table 1. Summary of urinary metabolites showing altered abundance in Hgd-/- mice. Direction of alteration and log2 
fold change is indicated in Hgd-/- (relative to Hgd+/-) and following nitisinone treatment in Hgd-/- (paired data; post-nitisinone 
relative to pre-nitisinone). P-values are false discovery rate adjusted. Where compounds were significantly different in 
positive and negative polarity, the result with the lowest fold change is provided. For compounds identified by accurate mass 
(AM) and retention time (RT), match criteria were accurate mass (±10ppm) and RT (±0.3mins) against a database generated 
in-house from metabolite standards. Compound identifications based on accurate mass match alone were with a mass 
window ±5ppm. 






Basis for compound 
identification  
HGA-sulfate 247.9996 2.6 ↑ 9.3 <0.0001 AM, in silico MS/MSa 
HGA 168.0434 3.4 ↑ 7.9 <0.0001 AM, RT, MS/MS 
HGA-glucuronide 344.075 2.4 ↑ 5 <0.0001 AM, in silico MS/MSa 
HGA-hydroxylsulfate 263.9931 2.8 ↑ 4.2 <0.0001 AM, in silico MS/MSa 
HGA-N-acetylcysteine 329.057 4.5 ↑ 4 <0.0001 AM 
Thymidine-5’-diphospho-alpha-D-
glucose 564.0758 2.4 ↑ 3.3 <0.0001 AM, RT 
Unknown 268.9662 2.6 ↑ 2.8 <0.0001  
Unknown 367.0289 3.4 ↑ 2.6 <0.0001  
DL-3,4-Dihydroxymandelic acid 184.037 1.9 ↑ 2.5 <0.0001 AM, RT 
HGA-hydrate 186.053 3.4 ↑ 2.4 <0.0001 AM 
Unknown 507.141 3.4 ↑ 2.4 <0.0001  
Acetyl-HGAb 210.053 6.2 ↑ 2.3 <0.0001 AM 
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Unknown 287.9939 6.0 ↑ 2.3 0.025  
Unknown 257.0758 3.5 ↑ 2.2 <0.0001  
Unknown 257.0391 3.4 ↑ 2.0 <0.0001  
2-Aminophenol 109.0534 1.9 ↑ 1.7 0.035 AM, RT 
Unknown 294.0949 3.6 ↑ 1.7 <0.001  
p-Hydroxyphenylacetic acid 152.0478 5.5 ↑ 1.6 <0.0001 AM, RT 
Unknown 361.0827 1.7 ↑ 1.5 <0.001  
3-Dehydroshikimic acid 172.0373 1.8 ↑ 1.2 <0.01 AM, RT 
Hydroxymethyl-HGA 198.0526 4.8 ↑ 1.1 <0.0001 AM 
Aceturic acid 117.0426 1.7 ↑ 0.94 <0.01 AM, RT 
Nicotinic acid 123.032 1.8 ↑ 0.8 0.015 AM, RT 
4-Hydroxybenzaldehyde 122.0368 5.6 ↑ 0.8 0.014 AM, RT, MS/MS 
Vanillylmandelic acid 198.0528 3.3 ↑ 0.75 <0.01 AM, RT 
N-Acetyl-serine 147.0532 1.6 ↑ 0.66 <0.01 AM, RT, MS/MS 
N-Acetylaspartate 175.0481 1.8 ↑ 0.64 0.018 AM, RT, MS/MS 
Xanthosine 284.0762 3.4 ↑ 0.53 0.028 AM, RT, MS/MS 
N-Alpha-acetyl-L-asparagine 174.0641 1.6 ↑ 0.52 <0.01 AM, RT, MS/MS 
N-Acetyl-L-phenylalanine 207.0895 6.8 ↑ 0.52 0.049 AM, RT, MS/MS 
3,5-Cyclic-AMP 329.0525 3.4 ↑ 0.44 0.012 AM, RT, MS/MS 
Malic acid 134.0211 1.5 ↓ 2.6 <0.001 AM, RT, MS/MS 
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Citric acid 192.0278 1.7 ↓ 2.1 <0.001 AM, RT, MS/MS 
Unknown 256.0582 5.0 ↓ 2.1 <0.001  
Inosine 5’-monophosphate 348.05 1.8 ↓ 2 <0.001 AM, RT, MS/MS 
Unknown 242.0427 4.0 ↓ 1.7 <0.0001  
Unknown 362.086 9.6 ↓ 1.6 <0.01  
Ascorbic acid 176.0321 1.6 ↓ 1.4 <0.01 AM, RT, MS/MS 
Succinic acid  118.0266 2.0 ↓ 1.1 <0.0001 AM, RT, MS/MS 
3-Methyl-glutaric acid 146.0579 5.1 ↓ 0.82 0.029 AM, RT 
N-Acetyl-L-glutamic acid 189.0637 2.1 ↓ 0.76 <0.01 AM, RT, MS/MS 
Citramalic acid 148.039 2.6 ↓ 0.7 <0.0001 AM, RT, MS/MS 
L-anserine 240.1222 1.3 ↓ 0.59 <0.01 AM, RT 
2,3-Cyclic AMP 329.0525 2.7 ↓ 0.58 <0.01 AM, RT 
O-Succinyl-L-homoserine 219.0743 2.0 ↓ 0.35 0.019 AM, RT 
 
a MS/MS compound identification based on matching experimental spectra with in silico fragmentation data, using Molecular Structure Correlator 
(MSC) with score threshold >65%; all other MS/MS matches were against spectra from the MassHunter METLIN metabolite PCDL accurate mass 
library (build 07.00). 
b Acetyl-HGA failed quality control filtering (CV >25% across replicate injections of QC pooled samples; due to suspected compound stability issue 





Table 2. The effect of nitisinone treatment in Hgd-/- mice and patients with AKU on the abundance of urinary 
metabolites altered in Hgd-/- vs Hgd+/- mice. The compounds that showed differences between Hgd-/- vs Hgd+/- mice 
(Table 1) were examined in two additional datasets. Paired t-tests were employed to compare the abundances at baseline 
versus 1 week on nitisinone (4mg/L, in drinking water) for Hgd-/- mice and 24 months on 2mg daily nitisinone for patients 
with AKU. Only compounds with false discovery rate adjusted p<0.05 pre- vs on nitisinone in mouse or human are 
displayed. Direction of alteration and log2 fold change are indicated. Where compounds were significantly different in 
positive and negative polarity, the result with the lowest fold change is provided. Note: no fold change indicated for 
hydroxymethyl-HGA in humans, as this compound was not detected for any patient on nitisinone. 
ND: compound not detected at baseline or on nitisinone. 

















HGA-glucuronide 344.075 2.4 ↓ 2.4 <0.0001  ↓ 2.4 <0.0001 
HGA-hydroxylsulfate 263.9931 2.8 ↓ 2.3 <0.0001  ND   
2-Aminophenol 109.0534 1.9 ↓ 2.2 <0.001  -   
HGA-sulfate  247.9996 2.6 ↓ 2.2 <0.0001  ↓ 3.5 <0.0001 
Unknown 268.9662 2.6 ↓ 2.0 <0.0001  ND   
DL-3,4-Dihydroxymandelic acid 184.037 1.9 ↓ 1.6 <0.0001  -   
HGA 168.0434 3.4 ↓ 1.6 <0.0001  ↓ 3.4 <0.0001 
Hydroxymethyl-HGA  198.0526 4.8 ↓ 1.1 <0.001  ↓ - <0.0001 
Aceturic acid 117.0426 1.7 ↓ 1.1 <0.0001  -   
Xanthosine 284.0762 3.4 ↓ 1 <0.0001  ↓ 2.2 <0.0001 
41 
HGA-hydrate 186.053 3.4 ↓ 0.8 <0.0001  ↓ 3.8 <0.0001 
HGA-N-acetylcysteine  329.057 4.5 ↓ 0.7 <0.001  -   
N-Acetyl-serine 147.0532 1.6 ↓ 0.5 0.031  -   
Nicotinic acid 123.032 1.8 ↓ 0.4 0.014  -   
3,5-Cyclic-AMP 329.0525 3.4 ↓ 0.3 0.041  ↓ 2 <0.0001 
Acetyl-HGA 210.053 6.2 -    ↓ 2.7 <0.0001 
Vanillylmandelic acid 198.0528 3.3 -    ↓ 1 <0.01 
unknown 257.0758 3.5 -    ↓ 0.9 0.035 
N-Alpha-acetyl-L-asparagine 174.0641 1.6 -    ↓ 0.4 <0.01 
Malic acid 134.0211 1.5 ND    ↑ 0.8 0.028 
3-Hydroxyphenylacetic acid 152.0478 5.5 ↑ 3.3 <0.0001  ↑ 3 <0.0001 
4-Hydroxybenzaldehyde 122.0368 5.6 ↑ 2.32 <0.0001  ↑ 6.6 <0.0001 
N-Acetyl-L-phenylalanine 207.0895 6.8 ↑ 1.8 <0.0001  -   
Unknown 294.0949 3.6 ↑ 1.8 <0.0001  ↓ 0.6 <0.001 
Unknown 362.086 9.6 ↑ 1.4 <0.0001  ND   
Citric acid 192.0278 1.7 ↑ 1.2 <0.01  -   
N-Acetylaspartate 175.0481 1.8 ↑ 0.9 0.023  -   
Citramalic acid 148.039 2.6 ↑ 0.8 0.023  -   
N-Acetyl-L-glutamic acid 189.064 2.1 ↑ 0.8 <0.0001  -   
3-Methyl-glutaric acid 146.0579 5.1 ↑ 0.4 <0.01  ↑ 1.7 0.041 
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